

Figure 1

Combination Therapy with CI-1033 and Taxotere Against Advanced H125 NSCLC Xenografts




Figure 2

Combination Therapy with CI-1033 and Radiation Against Advanced Murine Rif-1 Sarcoma





Figure 3

Preclinical Schedule Dependence of CI-1033 *In Vitro*

Cell Culture Data First Suggested Schedule Dependence of Taxol When Combined with CI-1033




Figure 4

